Biomarkers for lower urinary tract symptoms (luts)
AssigneeThe Regents of the University of Michigan
InventorsMitchell B. Berger, Andrew Johnston
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for the characterization of a subject's predisposition to developing lower urinary tract symptoms (LUTS). In particular, biomarkers are provided that identify the likelihood that a subject with develop LUTS concomitant with pelvic organ prolapse (POP), and/or the likelihood that LUTS will persist after surgical repair of POPS.
Claims28
A method for assessing the likelihood a human female subject will develop LUTS comprising detecting the level of one or more biomarkers in a sample, wherein the level of the one or more biomarkers is indicative of likelihood of developing LUTS, and wherein the biomarkers are one or more biomarkers selected from the list consisting of:
- hbegf, IL-6, ngf, IL-10, Gro, SCD40L, MCP-1, IL-3, IP-10, IL-12, MCP 3, and MIP-1b.
2-4. (canceled)
6-8. (canceled)
The method of claim 8, wherein the subject suffers from pelvic organ prolapse (POP).
(canceled)
(canceled)
A method of determining a treatment course for a subject suffering from pelvic organ prolapse (POP) with concomitant lower urinary tract symptoms (LUTS):
- (a) assessing the likelihood that LUTS will persist after surgical treatment of POP based on the level of one or more biomarkers in a sample from the subject;
- (b) selecting a suitable treatment course for the subject, wherein:
- (i) surgery alone is indicated if the likelihood that LUTS will persist after surgical treatment of POP is low;
- and
- (ii) medical treatment for LUTS with or without surgery for POP is indicated if the likelihood that LUTS will persist after surgical treatment of POP is high.
(canceled)
A method for assessing the likelihood that the subject from which a sample was obtained will develop LUTS, comprising:
- (a) receiving the sample obtained from the subject;
- (b) quantitating the levels of a plurality of biomarkers indicative of the likelihood that a subject will develop LUTS;
- and
- (c) generating a LUTS risk profile based on the levels of a plurality of biomarkers.
(canceled)
(canceled)
A kit for assessing the likelihood of LUTS comprising reagents for detecting the level of a plurality of biomarkers selected from the list consisting of:
- hbegf, IL-6, ngf, IL-10, Gro, SCD40L, MCP-1, IL-3, IP-10, IL-12, MCP 3, and MIP-1b.
32-35. (canceled)
Dependencies are inferred from the claim text.